‘Vaccinate my village’ strategy in Malawi: an effort to boost COVID-19 vaccination

Figures & data

Table 1. Effect of VMV strategy on national COVID-19 vaccine coverage.

	Proportion	95% CI	SD	Mean difference	Mann-Whitney U test	P-value	INFERENCE
BEFORE VMV	4.66	3.52–5.80	3.04	10.74	60.5	0.0001	significant
AFTER VMV	15.4	12.5–18.29	7.76

Figure 1. Proportion of population before and after VMV strategy who received a single dose of COVID-19 vaccine.

Table 2. Comparison of mean doses of COVID-19 vaccine across all 29 districts in four different phases.

	RCV-1		CVE		RCV-2		VMV
	MEAN	SD	MEAN	SD	MEAN	SD	MEAN	SD	KW TEST/ANNOVA	P VALUE	INFERENCE
Balaka	1500	1002	3707	2923	3199	1795	10,076	4544	12.299	0.006	S
Blantyre	16,635	13,050	16,922	13,701	3631	1564	15,077	3420	5.420	0.144	NS
Chikwawa	1674	504	4194	1167	377	194	6494	4788	9.542	0.023	S
Chiradzulu	811	427	3473	3096	731	931	3259	2624	5.816	0.121	NS
Chitipa	2532	1000	6503	2852	2397	697	4995	1655	10.372	0.016	S
Dedza	3989	3678	14,014	8161	1992	234	12,007	6571	6.841	0.077	S
Dowa	10,452	10,935	29,702	9532	7263	4497	26,004	8090	8.489	0.037	S
Karonga	3125	1170	8473	1496	2193	1079	7464	3464	12.293	0.006	S
Kasungu	9817	6201	17,990	4209	4869	1889	34,337	10,095	12.888	0.005	S
Likoma	122	131	225	228	7	3	418	940	3.074	0.380	NS
Lilongwe	26,540	17,067	33,262	21,391	10,377	3043	31,583	10,868	6.395^#	0.094	NS
Machinga	1947	3209	9459	5407	5652	9596	77,561	62,859	12.907	0.005	S
Mangochi	1289	1274	11,024	5184	1269	873	31,505	21,569	13.551	0.004	S
Mchinji	2312	1902	12,273	5049	1780	1020	6285	2779	10.583	0.014	S
Mulanje	1352	795	4276	3688	1850	716	7300	2960	11.321	0.010	S
Mwanza	514	442	836	477	92	120	3018	1082	13.460	0.004	S
Mzimba North	8369	5294	20,980	13,145	4570	2069	11,954	7869	4.462^#	0.216	NS
Mzimba South	3651	2049	11,483	6497	2172	2451	9178	7488	5.988	0.112	NS
Neno	733	439	1374	699	87	151	2136	1617	7.616	0.055	S
Nkhata Bay	2117	887	7433	1788	1799	77	7607	3455	12.663	0.005	S
Nkhota kota	2828	1917	8830	2203	6218	3277	7525	3796	7.314^#	0.063	NS
Nsanje	2741	2040	8399	3221	3261	1750	12,830	10,026	12.063	0.007	S
Ntcheu	3067	1427	7881	3499	1853	1276	7079	3734	8.242^#	0.041	S
Ntchisi	7545	4912	11,978	9186	1773	157	9925	6008	7.995	0.046	S
Phalombe	1004	1129	2103	1372	621	704	1719	1613	3.174	0.366	NS
Rumphi	2456	1186	10,072	6662	1988	710	12,026	3551	13.351	0.004	S
Salima	2896	1084	14,863	1027	4146	4082	5908	3192	7.457	0.059	S
Thyolo	1238	674	2130	1105	612	384	4055	1869	12.888	0.005	S
Zomba	5126	4204	5163	4224	869	504	6271	1741	5.219^#	0.156	NS
country	35,414	44,914	19,932	16,008	8032	7224	77,708	92,136	47.89	0.0001	S

#ANOVA test value (F), S: significant, NS: non-significant,

Figure 2. Monthly proportion of the COVID-19 vaccine, out of the total consumed doses.

Table 3. A comparison of mean doses of the COVID-19 vaccine between VMV versus RCV-1, CVE, and RCV-2.

				95% CONFIDENCE INTERVAL		RCV-1 versus CVE versus RCV-2 versus VMV
VMV versus	Mean Difference	Std. Error	Post hoc analysis p-value	Lower Bound	Upper Bound	F VALUE	P VALUE	INFERENCE
RCV-1	42,293.603	13,655.233	0.015	5616.64	78,970.56	9.93	0.001	Significant
CVE	57776.414	13,655.233	0.0001	21,099.45	94,453.38
RCV-2	69,675.966	13,655.233	0.0001	32,999.00	106,352.93